Stryker Co. (NYSE:SYK) Stock Holdings Increased by Baskin Financial Services Inc.

Baskin Financial Services Inc. boosted its stake in shares of Stryker Co. (NYSE:SYK) by 0.7% during the third quarter, HoldingsChannel.com reports. The firm owned 111,382 shares of the medical technology company’s stock after acquiring an additional 785 shares during the period. Stryker makes up about 3.3% of Baskin Financial Services Inc.’s portfolio, making the stock its 15th largest holding. Baskin Financial Services Inc.’s holdings in Stryker were worth $40,238,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in SYK. Global Assets Advisory LLC bought a new position in Stryker during the first quarter valued at approximately $341,049,000. JPMorgan Chase & Co. lifted its stake in shares of Stryker by 10.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,651,403 shares of the medical technology company’s stock valued at $3,096,078,000 after purchasing an additional 813,311 shares during the last quarter. 1832 Asset Management L.P. boosted its holdings in Stryker by 146.9% in the first quarter. 1832 Asset Management L.P. now owns 878,669 shares of the medical technology company’s stock worth $314,449,000 after purchasing an additional 522,817 shares in the last quarter. American Century Companies Inc. increased its position in Stryker by 287.6% during the second quarter. American Century Companies Inc. now owns 505,608 shares of the medical technology company’s stock worth $172,033,000 after buying an additional 375,166 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Stryker by 1.0% during the first quarter. Vanguard Group Inc. now owns 31,459,393 shares of the medical technology company’s stock worth $11,258,373,000 after buying an additional 309,592 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the subject of several recent analyst reports. UBS Group upped their price target on Stryker from $351.00 to $366.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Stifel Nicolaus lowered their price target on Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Evercore ISI upped their price objective on shares of Stryker from $365.00 to $380.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Needham & Company LLC lifted their target price on shares of Stryker from $392.00 to $393.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Finally, Truist Financial boosted their target price on shares of Stryker from $345.00 to $370.00 and gave the stock a “hold” rating in a research report on Monday. Four analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $381.16.

Insider Transactions at Stryker

In related news, CFO Glenn S. Boehnlein sold 20,000 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the sale, the chief financial officer now owns 2,852 shares of the company’s stock, valued at approximately $949,716. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Stryker news, CFO Glenn S. Boehnlein sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the sale, the chief financial officer now directly owns 2,852 shares in the company, valued at approximately $949,716. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 190,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $323.46, for a total transaction of $61,457,400.00. Following the completion of the transaction, the director now owns 3,316,608 shares of the company’s stock, valued at $1,072,790,023.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 220,068 shares of company stock valued at $71,811,372 over the last three months. 5.50% of the stock is currently owned by corporate insiders.

Stryker Trading Up 0.4 %

Shares of SYK stock traded up $1.43 during trading hours on Wednesday, reaching $360.41. The company had a trading volume of 227,081 shares, compared to its average volume of 1,251,200. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.95. Stryker Co. has a 1-year low of $255.22 and a 1-year high of $374.63. The company has a 50 day moving average of $353.45 and a 200 day moving average of $342.96. The firm has a market cap of $137.35 billion, a price-to-earnings ratio of 40.02, a P/E/G ratio of 2.78 and a beta of 0.91.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. The firm had revenue of $5.42 billion for the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The company’s revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the business earned $2.54 earnings per share. On average, equities research analysts anticipate that Stryker Co. will post 12 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be issued a $0.80 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.20 annualized dividend and a yield of 0.89%. Stryker’s dividend payout ratio (DPR) is presently 35.67%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.